Patient specific circulating tumor DNA fingerprints to monitor treatment response across multiple tumors.

ABSTRACT:

Background

Circulating tumor DNA (ctDNA) offers a convenient way to monitor tumor progression and treatment response. Because tumor mutational profiles are highly variable from person to person, a fixed content panel may be insufficient to track treatment response in all patients.

Methods

We design ctDNA fingerprint panels specific to individual patients which are based on whole exome sequencing and target to high frequency clonal population clusters in patients. We test the fingerprint panels in 313 patients who together have eight tumor types (colorectal, hepatocellular, gastric, breast, pancreatic, and esophageal carcinomas and lung cancer and cholangiocarcinoma) and exposed to multiple treatment methods (surgery, chemotherapy, radiotherapy, targeted-drug therapy, immunot

SUBMITTER: Li J 

PROVIDER: S-EPMC7395971 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature